Medicines Formulary

Reports

Drug name	NICE TAs	Comments
Reflectant (Dundee) sunscreens		Unlicensed specials
Remifentanil injection
Resilizumab (Cinqaero®)	TA479 - Raslizumab for treating severe eosinophilic asthma	Hospital only
Ribociclib (Kisqali®)	TA496 - Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer TA593 - Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer TA687 - Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer	For hospital use only
Ringer's solution for injection
Risankivzub (Skyrizi®)	TA596 - Risankizumab for treating moderate to severe plaque psoriasis
Risperidone injection		APC verdict - present status = RED (Future status = AMBER with a framework in primary care before transfer - commissioning discussion)
Ritumixab infusion (Mabthera®, Truxima®)	TA195 - Drugs for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor
Rituximab	TA243 - Rituximab for the first-line treatment of stage III-IV follicular lymphoma TA193 - Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemia TA174 - Rituximab for the first-line treatment of chronic lymphocytic leukaemia TA137 - Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma TA65 - Rituximab for aggressive non-Hodgkin's lymphoma TA195 - Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor TA308 - Rituximab in combination with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis TA226 - Rituximab for the first-line maintenance treatment of follicular non-Hodgkin's lymphoma
Rivaroxaban tablets	TA170 - Venous thromboembolism - Rivaroxaban TA607 - Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery disease	BSSE APC preferred agent. This recommendation must only be taken into account after a patient and prescriber have discussed all treatment options (including warfarin) and only if they have no preference about which medicine they want to use. Red use following hip and knee surgery – full course of treatment supplied on discharge

First page
Previous page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
Next page
Last page

Drug status key

Formulary drugs are allocated a traffic light status. This provides guidance on where clinical and prescribing responsibilities lie in regard to the initiation and maintenance of prescribing.

Grey

Positive NICE TA and/or awaiting local clarification on place in therapy. Please contact your medicines optimisation team for more information.

Red

Initiation and maintenance of prescribing by specialists only.

Amber

Initiation and maintenance of prescribing by specialists and transfer to primary care prescribing when appropriate, or in primary care following a specialists recommendation. Prior to initiation some medicines may require committee agreement or a framework to support safe transfer and maintenance.

Green

Initiation and maintenance of prescribing by specialists, GPs and other qualified clinicians.

Blue

Under review at University Hospitals Birmingham NHS Foundation Trust.